Microinjection of 26RFa, an endogenous ligand for the glutamine RF-amide peptide receptor (QRFP receptor), into the rostral ventromedial medulla (RVM), locus coelureus (LC), and periaqueductal grey (PAG) produces an analgesic effect in rats

[1]  Isabel Martins,et al.  Reticular Formation and Pain: The Past and the Future , 2017, Front. Neuroanat..

[2]  D. Larhammar,et al.  The Arg–Phe‐amide peptide 26RFa/glutamine RF‐amide peptide and its receptor: IUPHAR Review 24 , 2017, British journal of pharmacology.

[3]  J. Neale,et al.  A role for the locus coeruleus in the analgesic efficacy of N-acetylaspartylglutamate peptidase (GCPII) inhibitors ZJ43 and 2-PMPA , 2017, Molecular pain.

[4]  Masahiko Watanabe,et al.  QRFP-Deficient Mice Are Hypophagic, Lean, Hypoactive and Exhibit Increased Anxiety-Like Behavior , 2016, PloS one.

[5]  F. Porreca,et al.  Descending pain modulation and chronification of pain , 2014, Current opinion in supportive and palliative care.

[6]  T. Sorg,et al.  Endogenous mammalian RF-amide peptides, including PrRP, kisspeptin and 26RFa, modulate nociception and morphine analgesia via NPFF receptors , 2013, Neuropharmacology.

[7]  H. Vaudry,et al.  The RFamide neuropeptide 26RFa and its role in the control of neuroendocrine functions , 2011, Frontiers in Neuroendocrinology.

[8]  Toshihiko Yamada,et al.  Anti-allodynic effects of intrathecally and intracerebroventricularly administered 26RFa, an intrinsic agonist for GRP103, in the rat partial sciatic nerve ligation model , 2011, Peptides.

[9]  Toshihiko Yamada,et al.  Intracerebroventricular administration of 26RFa produces an analgesic effect in the rat formalin test , 2009, Peptides.

[10]  H. Vaudry,et al.  Distribution of 26RFa binding sites and GPR103 mRNA in the central nervous system of the rat , 2007, The Journal of comparative neurology.

[11]  H. Vaudry,et al.  Behavioral effects of 26RFamide and related peptides , 2006, Peptides.

[12]  Ya-li Peng,et al.  In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist , 2006, Peptides.

[13]  F. Vandesande,et al.  Identification of 26RFa, a hypothalamic neuropeptide of the RFamide peptide family with orexigenic activity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Parmentier,et al.  Pharmacological characterization of human NPFF(1) and NPFF(2) receptors expressed in CHO cells by using NPY Y(1) receptor antagonists. , 2002, European journal of pharmacology.

[15]  W D Willis,et al.  Periaqueductal gray stimulation-induced inhibition of nociceptive dorsal horn neurons in rats is associated with the release of norepinephrine, serotonin, and amino acids. , 1999, The Journal of pharmacology and experimental therapeutics.

[16]  A. Beck‐Sickinger,et al.  The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. , 1994, European journal of pharmacology.

[17]  T. Yamamoto,et al.  Comparison of the antinociceptive effects of pre- and posttreatment with intrathecal morphine and MK801, an NMDA antagonist, on the formalin test in the rat. , 1992, Anesthesiology.

[18]  F. Porreca,et al.  The rat paw formalin test: comparison of noxious agents , 1990, Pain.

[19]  A I Basbaum,et al.  The origin of descending pathways in the dorsolateral funiculus of the spinal cord of the cat and rat: Further studies on the anatomy of pain modulation , 1979, The Journal of comparative neurology.